Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,1-dichloroethene | decreases expression | ISO | Egfl6 (Mus musculus) | 6480464 | vinylidene chloride results in decreased expression of EGFL6 mRNA | CTD | PMID:26682919 | 1-naphthyl isothiocyanate | decreases expression | EXP | | 6480464 | 1-Naphthylisothiocyanate results in decreased expression of EGFL6 mRNA | CTD | PMID:30723492 | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Estradiol] results in increased expression of EGFL6 mRNA | CTD | PMID:26496021 | 2,3',4,4',5-Pentachlorobiphenyl | increases expression | ISO | Egfl6 (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:31388691 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin affects the expression of EGFL6 mRNA | CTD | PMID:36370075 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of EGFL6 mRNA | CTD | PMID:33387578 | 4,4'-sulfonyldiphenol | increases expression | ISO | Egfl6 (Mus musculus) | 6480464 | bisphenol S results in increased expression of EGFL6 mRNA | CTD | PMID:30951980 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of EGFL6 mRNA | CTD | PMID:24780913 | 6-propyl-2-thiouracil | decreases expression | EXP | | 6480464 | Propylthiouracil results in decreased expression of EGFL6 mRNA | CTD | PMID:30047161 | aflatoxin B1 | decreases methylation | ISO | EGFL6 (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of EGFL6 gene | CTD | PMID:27153756 | aflatoxin B1 | increases methylation | ISO | EGFL6 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased methylation of EGFL6 intron | CTD | PMID:30157460 | all-trans-retinoic acid | multiple interactions | ISO | Egfl6 (Mus musculus) | 6480464 | [bisphenol A co-treated with Tretinoin] results in decreased expression of EGFL6 mRNA and [bisphenol F co-treated with Tretinoin] results in decreased expression of EGFL6 mRNA | CTD | PMID:30951980 | amiodarone | increases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Amiodarone results in increased expression of EGFL6 mRNA | CTD | PMID:19774075 | amitrole | decreases expression | EXP | | 6480464 | Amitrole results in decreased expression of EGFL6 mRNA | CTD | PMID:30047161 | antirheumatic drug | increases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Antirheumatic Agents results in increased expression of EGFL6 mRNA | CTD | PMID:24449571 | arsenous acid | decreases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Arsenic Trioxide results in decreased expression of EGFL6 mRNA | CTD | PMID:26705709 | benzo[a]pyrene | affects methylation | ISO | EGFL6 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of EGFL6 5' UTR and Benzo(a)pyrene affects the methylation of EGFL6 promoter | CTD | PMID:27901495 | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Estradiol] results in increased expression of EGFL6 mRNA | CTD | PMID:26496021 | bisphenol A | increases expression | ISO | Egfl6 (Mus musculus) | 6480464 | bisphenol A results in increased expression of EGFL6 mRNA | CTD | PMID:32156529 | bisphenol A | multiple interactions | ISO | EGFL6 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of EGFL6 gene | CTD | PMID:31601247 | bisphenol A | multiple interactions | ISO | Egfl6 (Mus musculus) | 6480464 | [bisphenol A co-treated with Tretinoin] results in decreased expression of EGFL6 mRNA | CTD | PMID:30951980 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of EGFL6 gene | CTD | PMID:28505145 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of EGFL6 mRNA | CTD | PMID:25181051 more ... | bisphenol F | multiple interactions | ISO | Egfl6 (Mus musculus) | 6480464 | [bisphenol F co-treated with Tretinoin] results in decreased expression of EGFL6 mRNA | CTD | PMID:30951980 | cadmium atom | decreases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Cadmium results in decreased expression of EGFL6 mRNA | CTD | PMID:21120746 | CGP 52608 | multiple interactions | ISO | EGFL6 (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to EGFL6 gene] | CTD | PMID:28238834 | chloroprene | decreases expression | ISO | Egfl6 (Mus musculus) | 6480464 | Chloroprene results in decreased expression of EGFL6 mRNA | CTD | PMID:23125180 | cisplatin | decreases response to substance | ISO | EGFL6 (Homo sapiens) | 6480464 | EGFL6 mRNA results in decreased susceptibility to Cisplatin | CTD | PMID:25199881 | Cuprizon | increases expression | EXP | | 6480464 | Cuprizone results in increased expression of EGFL6 mRNA | CTD | PMID:27523638 | cyclosporin A | increases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of EGFL6 mRNA | CTD | PMID:33631201 | cytarabine | decreases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Cytarabine results in decreased expression of EGFL6 mRNA | CTD | PMID:21198554 | diarsenic trioxide | decreases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Arsenic Trioxide results in decreased expression of EGFL6 mRNA | CTD | PMID:26705709 | dioxygen | multiple interactions | EXP | | 6480464 | [dan-shen root extract co-treated with Andrographis paniculata extract] inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of EGFL6 mRNA] and [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of EGFL6 mRNA | CTD | PMID:33729688 | diquat | decreases expression | ISO | Egfl6 (Mus musculus) | 6480464 | Diquat results in decreased expression of EGFL6 mRNA | CTD | PMID:36851058 | dorsomorphin | multiple interactions | ISO | EGFL6 (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFL6 mRNA | CTD | PMID:27188386 | doxorubicin | decreases response to substance | ISO | EGFL6 (Homo sapiens) | 6480464 | EGFL6 mRNA results in decreased susceptibility to Doxorubicin | CTD | PMID:25199881 | fulvestrant | multiple interactions | ISO | EGFL6 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of EGFL6 gene | CTD | PMID:31601247 | gentamycin | decreases expression | EXP | | 6480464 | Gentamicins results in decreased expression of EGFL6 mRNA | CTD | PMID:22061828 and PMID:33387578 | indometacin | increases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Indomethacin results in increased expression of EGFL6 mRNA | CTD | PMID:24737281 | lipopolysaccharide | multiple interactions | ISO | EGFL6 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of EGFL6 mRNA | CTD | PMID:35811015 | methimazole | decreases expression | EXP | | 6480464 | Methimazole results in decreased expression of EGFL6 mRNA | CTD | PMID:30047161 | methotrexate | affects expression | ISO | Egfl6 (Mus musculus) | 6480464 | Methotrexate affects the expression of EGFL6 mRNA | CTD | PMID:18502557 | methotrexate | decreases response to substance | ISO | EGFL6 (Homo sapiens) | 6480464 | EGFL6 mRNA results in decreased susceptibility to Methotrexate | CTD | PMID:25199881 | nitrofen | increases expression | EXP | | 6480464 | nitrofen results in increased expression of EGFL6 mRNA | CTD | PMID:33484710 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of EGFL6 mRNA | CTD | PMID:25729387 | oxaliplatin | decreases expression | EXP | | 6480464 | oxaliplatin results in decreased expression of EGFL6 mRNA | CTD | PMID:25729387 | ozone | multiple interactions | ISO | Egfl6 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of EGFL6 mRNA and [Air Pollutants results in increased abundance of Ozone] which results in increased expression of EGFL6 mRNA | CTD | PMID:34911549 | paclitaxel | decreases response to substance | ISO | EGFL6 (Homo sapiens) | 6480464 | EGFL6 mRNA results in decreased susceptibility to Paclitaxel | CTD | PMID:25199881 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of EGFL6 mRNA | CTD | PMID:33387578 | paraquat | decreases expression | EXP | | 6480464 | Paraquat results in decreased expression of EGFL6 mRNA | CTD | PMID:32680482 | progesterone | decreases expression | ISO | Egfl6 (Mus musculus) | 6480464 | Progesterone results in decreased expression of EGFL6 mRNA | CTD | PMID:22238285 | rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of EGFL6 mRNA | CTD | PMID:28374803 | rotenone | increases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Rotenone results in increased expression of EGFL6 mRNA | CTD | PMID:29955902 and PMID:36586010 | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | EGFL6 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of EGFL6 mRNA | CTD | PMID:35811015 | SB 431542 | multiple interactions | ISO | EGFL6 (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFL6 mRNA | CTD | PMID:27188386 | silicon dioxide | decreases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Silicon Dioxide results in decreased expression of EGFL6 mRNA | CTD | PMID:25351596 | sodium arsenite | decreases expression | ISO | Egfl6 (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of EGFL6 mRNA | CTD | PMID:37682722 | Soman | decreases expression | EXP | | 6480464 | Soman results in decreased expression of EGFL6 mRNA | CTD | PMID:19281266 | sulfadimethoxine | decreases expression | EXP | | 6480464 | Sulfadimethoxine results in decreased expression of EGFL6 mRNA | CTD | PMID:30047161 | sulforaphane | decreases expression | ISO | Egfl6 (Mus musculus) | 6480464 | sulforaphane results in decreased expression of EGFL6 mRNA | CTD | PMID:30529165 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of EGFL6 mRNA | CTD | PMID:25729387 | topotecan | decreases response to substance | ISO | EGFL6 (Homo sapiens) | 6480464 | EGFL6 mRNA results in decreased susceptibility to Topotecan | CTD | PMID:25199881 | trichostatin A | increases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | trichostatin A results in increased expression of EGFL6 mRNA | CTD | PMID:24935251 | valproic acid | affects expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of EGFL6 mRNA | CTD | PMID:25979313 | valproic acid | increases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of EGFL6 mRNA | CTD | PMID:28001369 | valproic acid | increases expression | ISO | Egfl6 (Mus musculus) | 6480464 | Valproic Acid results in increased expression of EGFL6 mRNA | CTD | PMID:24896083 | valproic acid | decreases methylation | ISO | EGFL6 (Homo sapiens) | 6480464 | Valproic Acid results in decreased methylation of EGFL6 gene | CTD | PMID:29154799 | vancomycin | increases expression | ISO | Egfl6 (Mus musculus) | 6480464 | Vancomycin results in increased expression of EGFL6 mRNA | CTD | PMID:18930951 | vinclozolin | affects expression | EXP | | 6480464 | vinclozolin affects the expression of EGFL6 mRNA | CTD | PMID:19015723 | vincristine | decreases response to substance | ISO | EGFL6 (Homo sapiens) | 6480464 | EGFL6 mRNA results in decreased susceptibility to Vincristine | CTD | PMID:25199881 | vorinostat | multiple interactions | ISO | EGFL6 (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFL6 mRNA | CTD | PMID:27188386 | vorinostat | increases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | vorinostat results in increased expression of EGFL6 mRNA | CTD | PMID:26272509 | zoledronic acid | decreases expression | ISO | EGFL6 (Homo sapiens) | 6480464 | zoledronic acid results in decreased expression of EGFL6 mRNA | CTD | PMID:24714768 | |